Sample size adaptation in fixed-dose combination drug trial.
Statistical testing in clinical trials can be complex when the statistical distribution of the test statistic involves a nuisance parameter. Some type of nuisance parameters such as standard deviation of a continuous response variable can be handled without too much difficulty. Other type of nuisance parameters, specifically associated with the main parameter under testing, can be difficult to handle. Without knowledge of the possible value of such a nuisance parameter, the maximum type I error associated with testing the main parameter may occur at an extreme value of the nuisance parameter. A well known example is the intersection-union test for comparing a combination drug with its two component drugs where the nuisance parameter is the mean difference between the two components. Knowledge of the possible range of value of this mean difference may help enhance the clinical trial design. For instance, if the interim internal data suggest that this mean difference falls into a possible range of value, then the sample size may be reallocated after the interim look to possibly improve the efficiency of statistical testing. This research sheds some light into possible power advantage from such a sample size reallocation at the interim look.
Division of Biometrics I, OB/OTS/CDER, U.S. Food and Drug Administration, Silver Spring , MD 20993-0002, USA. hsienming.hung@fda.hhs.gov
H M
HM
James Hung
Sue-Jane
SJ
Wang
D000465:Algorithms; D001699:Biometry; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data*; D004359:Drug Therapy, Combination / Q000706:statistics & numerical data*; D005163:Factor Analysis, Statistical; D006801:Humans; D015233:Models, Statistical; D012107:Research Design / Q000706:statistics & numerical data; D018401:Sample Size